These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20613506)

  • 1. Atypical hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Hematol; 2010 Sep; 17(5):432-8. PubMed ID: 20613506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
    Fakhouri F; Frémeaux-Bacchi V; Loirat C
    Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.
    Lapeyraque AL; Frémeaux-Bacchi V; Robitaille P
    Pediatr Nephrol; 2011 Apr; 26(4):621-4. PubMed ID: 21161283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation.
    Carr R; Cataland SR
    Ann Hematol; 2013 Jun; 92(6):845-6. PubMed ID: 23154867
    [No Abstract]   [Full Text] [Related]  

  • 6. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
    Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
    Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
    Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative complement pathway assessment in patients with atypical HUS.
    Roumenina LT; Loirat C; Dragon-Durey MA; Halbwachs-Mecarelli L; Sautes-Fridman C; Fremeaux-Bacchi V
    J Immunol Methods; 2011 Feb; 365(1-2):8-26. PubMed ID: 21215749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical hemolytic uremic syndrome.
    Kavanagh D; Goodship TH; Richards A
    Semin Nephrol; 2013 Nov; 33(6):508-30. PubMed ID: 24161037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement therapy in atypical haemolytic uraemic syndrome (aHUS).
    Wong EK; Goodship TH; Kavanagh D
    Mol Immunol; 2013 Dec; 56(3):199-212. PubMed ID: 23810412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.
    Tschumi S; Gugger M; Bucher BS; Riedl M; Simonetti GD
    Pediatr Nephrol; 2011 Nov; 26(11):2085-8. PubMed ID: 21877169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic Uremic Syndrome in Pregnancy and Postpartum.
    Bruel A; Kavanagh D; Noris M; Delmas Y; Wong EKS; Bresin E; Provôt F; Brocklebank V; Mele C; Remuzzi G; Loirat C; Frémeaux-Bacchi V; Fakhouri F
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1237-1247. PubMed ID: 28596415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.
    Mache CJ; Acham-Roschitz B; Frémeaux-Bacchi V; Kirschfink M; Zipfel PF; Roedl S; Vester U; Ring E
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1312-6. PubMed ID: 19556379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
    Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
    Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).
    Roumenina LT; Roquigny R; Blanc C; Poulain N; Ngo S; Dragon-Durey MA; Frémeaux-Bacchi V
    Methods Mol Biol; 2014; 1100():237-47. PubMed ID: 24218264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
    Belingheri M; Possenti I; Tel F; Paglialonga F; Testa S; Salardi S; Ardissino G
    Pediatrics; 2014 Jun; 133(6):e1769-71. PubMed ID: 24843058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
    Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
    Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.